Spero Therapeutics Inc (SPRO) is not a strong buy for a beginner investor with a long-term focus at this time. The company is facing significant financial challenges, including a steep decline in revenue and net income, alongside insider selling activity. Technical indicators do not show a clear upward trend, and there are no positive catalysts or strong trading signals to justify immediate investment.

Technical Analysis

The MACD is negative and expanding (-0.0136), RSI is neutral at 29.097, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 2.188), but there is no strong bullish signal.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

NULL identified. No recent news or significant events to drive positive sentiment.

Neutral/Negative Catalysts

Insider selling has increased by 312.04% over the last month, indicating potential lack of confidence from company insiders. Financial performance has deteriorated significantly YoY, with revenue and net income dropping by 59.60% and 56.95%, respectively.

Financial Performance

In Q3 2025, revenue dropped to $5.44M (-59.60% YoY), net income fell to -$7.38M (-56.95% YoY), and EPS decreased to -0.13 (-59.38% YoY). Gross margin remained flat at 100%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

2 Analyst Rating

Wall Street analysts forecast SPRO stock price to rise

0 Buy

2 Hold

0 Sell

Hold

Current: 2.190

Low

Averages

High